bioRxiv Science⌕ Search

Biology subjects

Momnougui, S. M. E.

Publications and source records attributed to Momnougui, S. M. E..

2 recordsLinked to original sources

Development of an Integrated Single-Cell and Spatial Transcriptomics Atlas of Healthy Human Skin Focusing on the Pilosebaceous Unit

Single-cell and spatial transcriptomics have transformed our ability to chart human tissue organization at unprecedented resolution. These technologies enable the construction of high-quality reference atlases, essential for mapping healthy tissue architecture and identifying robust gene markers. We developed the healthy Human Skin Cell Atlas (HSCA), systematically integrating 34 public datasets and totaling 821,464 cells, with curated metadata and harmonized cell type nomenclature to ensure consistency. We place particular emphasis on the pilosebaceous unit, a key epithelial structure critical for both homeostasis and pathology. While prior studies captured the interfollicular epidermis and immune landscape in detail, deeper hair follicle regions remained under-characterized. By leveraging high-resolution spatial transcriptomics (Visium HD), we spatially resolved and transcriptionally defined the lower hair follicle compartments and pinpointed signalling hubs. Furthermore, the HSCA enables the detection of cell types not visible in standalone datasets, such as Merkel cells. Our results illustrate the value of the integrated single-cell atlas and spatial data in refining tissue organization and highlight the PSU as a complex and diverse epithelial niche.

bioinformatics↗

Safety and immunogenicity of an adjuvanted human onchocerciasis vaccine candidate, OvMANE1: preclinical evaluation in mice model

Onchocerciasis, caused by the filarial worm Onchocerca volvulus, remains a major public health challenge due to the limitations of ivermectin-based control strategies, thereby, highlighting the need for more innovative tools like vaccines. This study investigated the safety and immunogenicity of a novel multi-epitope chimeric antigen, OvMANE1 formulated with Freunds adjuvant, in BALB/c mice. Following mice immunization at three time points of 2-week intervals, adjuvanted-OvMANE1 exhibited a promising safety profile, revealing neither any physical signs of toxicity nor behavioural abnormalities. Immunological assays showed significant increases in total IgG levels after the first (p = 0.0260) and final booster doses (p = 0.026). Interestingly, total IgG (p = 0.0086) and IgG1 (p = 0.0465) levels also increased significantly over the study period highlighting the ability of OvMANE1 to sustain humoral immunity. Moreover, cellular responses were significantly enhanced, with elevated leukocyte count (p = 0.0190) and increased lymphocyte activity (p = 0.0397) observed in the adjuvanted-OvMANE1 group compared to the control. Indeed, total leukocytes increased progressively from day 0 to day 39, with significant differences recorded in the test group between doses: day 0 vs. day 14 (p = 0.0043) and day 14 vs. day 28 (p = 0.0079). The pronounced production of relevant antibodies and induction of cellular immunity strongly suggests that the antigen can elicit mixed Th1/Th2 responses and antibody-dependent cellular cytotoxicity (ADCC) targeting O. volvulus L3 and/or other larval stages of the parasite. These results clearly show the emergence of OvMANE1 as a promising vaccine candidate against human onchocerciasis. However, further studies to evaluate the antigens protective potential in other animal species are required.

immunology↗